Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for stiff heart? drug trial targets common heart failure

NCT ID NCT06122779

Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 4 times

Summary

This study tests an experimental drug (BMS-986435/MYK-224) in people with a specific type of heart failure where the heart pumps normally but is too stiff (HFpEF). The main goal is to check the drug's safety and how the body processes it. About 208 adults with stable symptoms will receive either the drug or a placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

227 people

The number who actually took part.

Started

Nov 2023

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria \- Adult participants with stable, symptomatic HFpEF with a normal heart pumping ability. Exclusion Criteria * Participants must not have a known diagnosis of obstructive or genetic hypertrophic cardiomyopathy or infiltrative/storage disorder such as cardiac amyloidosis, or any other acute or serious condition that could interfere with assessments during the study or may pose a risk to the participant. * Other protocol-defined Inclusion/Exclusion criteria apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Heart failure are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diastolic heart failure heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Heart failure

Contacts and locations

Locations

  • Local Institution - 0001

    Tullahoma, Tennessee, 37388-8260, United States

  • Local Institution - 0002

    Birmingham, Alabama, 35233, United States

  • Local Institution - 0003

    Miami, Florida, 33133-4223, United States

  • Local Institution - 0004

    Chicago, Illinois, 60611-5969, United States

  • Local Institution - 0005

    Hazel Crest, Illinois, 60429-2196, United States

  • Local Institution - 0007

    Hamilton, Ontario, L8L 2X2, Canada

  • Local Institution - 0008

    New York, New York, 10065-4805, United States

  • Local Institution - 0009

    Bergamo, 24127, Italy

  • Local Institution - 0010

    Valencia, 46010, Spain

  • Local Institution - 0012

    L'Hospitalet de Llobregat, Barcelona, 08907, Spain

  • Local Institution - 0013

    Lódz, Lódzkie, 92-213, Poland

  • Local Institution - 0015

    Houston, Texas, 77025-5253, United States

  • Local Institution - 0016

    Oklahoma City, Oklahoma, 73135-2607, United States

  • Local Institution - 0017

    Pisa, Tuscany, 56126, Italy

  • Local Institution - 0018

    Seville, 41014, Spain

  • Local Institution - 0019

    Naples, Campania, 80131, Italy

  • Local Institution - 0021

    El Palmar, Murcia, 30120, Spain

  • Local Institution - 0022

    San Donato Milanese, Lombardy, 20097, Italy

  • Local Institution - 0025

    Majadahonda, Madrid, 28222, Spain

  • Local Institution - 0026

    Madrid, 28034, Spain

  • Local Institution - 0028

    St Louis, Missouri, 63136-6111, United States

  • Local Institution - 0029

    Indianapolis, Indiana, 46260-1992, United States

  • Local Institution - 0031

    Bialystok, Podlaskie Voivodeship, 15-276, Poland

  • Local Institution - 0032

    Málaga, 29010, Spain

  • Local Institution - 0036

    Dallas, Texas, 75390, United States

  • Local Institution - 0037

    Toronto, Ontario, M4P 1E4, Canada

  • Local Institution - 0053

    Córdoba, Córdoba Province, X5003DCE, Argentina

  • Local Institution - 0054

    Ciudad del Libertador General San Martin, Buenos Aires, B1650BNB, Argentina

  • Local Institution - 0055

    Seoul, Seoul Teugbyeolsi, 06591, South Korea

  • Local Institution - 0056

    Junggu, Incheon Gwang'yeogsi, 22332, South Korea

  • Local Institution - 0059

    Rochester, New York, 14618-2668, United States

  • Local Institution - 0060

    Buenos Aires, 1407, Argentina

  • Local Institution - 0061

    San Miguel de Tucumán, Tucumán Province, T4000IAP, Argentina

  • Local Institution - 0062

    Oxford, OX3 9DU, United Kingdom

  • Local Institution - 0063

    Harrow, Greater London, HA1 3UJ, United Kingdom

  • Local Institution - 0064

    Wolverhampton, WV10 0QP, United Kingdom

  • Local Institution - 0065

    Stockton-on-Tees, TS19 8PE, United Kingdom

  • Local Institution - 0067

    Buenos Aires, C1431FWO, Argentina

  • Local Institution - 0069

    Salta, A4406BPF, Argentina

  • Local Institution - 0070

    Albany, New York, 12211, United States

  • Local Institution - 0071

    North Shields, Northumberland, NE29 8NH, United Kingdom

  • Local Institution - 0072

    Leeds, Yorkshire, LS1 3EX, United Kingdom

  • Local Institution - 0073

    Rosario, Santa Fe Province, 2000, Argentina

  • Local Institution - 0074

    Córdoba, X5000AOQ, Argentina

  • Local Institution - 0075

    London, SE1 7EH, United Kingdom

  • Local Institution - 0076

    Rochester, New York, 14621, United States

  • Local Institution - 0077

    Jacksonville, Florida, 32204-4748, United States

  • Local Institution - 0078

    Abington, Pennsylvania, 19001, United States

  • Local Institution - 0079

    Changsha, Hunan, 410011, China

  • Local Institution - 0080

    Luoyang, Henan, 471003, China

  • Local Institution - 0081

    Seoul, Seoul Teugbyeolsi, 03080, South Korea

  • Local Institution - 0082

    Hangzhou, Zhejiang, 310009, China

  • Local Institution - 0083

    Gwangju, Gwangju Gwang'yeogsi, 61469, South Korea

  • Local Institution - 0084

    Daejeon, Daejeon Gwang'yeogsi, 35015, South Korea

  • Local Institution - 0085

    Seoul, Seoul Teugbyeolsi, 03722, South Korea

  • Local Institution - 0086

    Pusan, Busan Gwangyeogsi, 49241, South Korea

  • Local Institution - 0087

    Guangzhou, Guangdong, 510120, China

  • Local Institution - 0088

    Daegu, 42601, South Korea

  • Local Institution - 0089

    Beijing, Beijing Municipality, 100730, China

  • Local Institution - 0090

    Córdoba, Córdoba Province, 5000, Argentina

  • Local Institution - 0091

    Okayama, Okayama-ken, 702-8055, Japan

  • Local Institution - 0092

    Himeji-Shi, Hyōgo, 672-8044, Japan

  • Local Institution - 0093

    Kishiwada, Osaka, 596-0042, Japan

  • Local Institution - 0094

    Rosedale, New York, 11422-1320, United States

  • Local Institution - 0095

    Durham, North Carolina, 27710-4000, United States

  • Local Institution - 0096

    Lakewood, Colorado, 80228-1710, United States

  • Local Institution - 0097

    Dundee, DD1 9SY, United Kingdom

  • Local Institution - 0098

    Seongnam, Gyeonggido, 13620, South Korea

  • Local Institution - 0099

    Miami, Florida, 33136-2107, United States

  • Local Institution - 0100

    Kanazawa, Ishikawa-ken, 920-8650, Japan

  • Local Institution - 0101

    Bristol, BS2 8HW, United Kingdom

  • Local Institution - 0102

    Santa Fe, S3000FWO, Argentina

  • Local Institution - 0103

    Takatsuki-Shi, Osaka, 569-1045, Japan

  • Local Institution - 0104

    Austin, Texas, 78756-4080, United States

  • Local Institution - 0105

    Brooklyn, New York, 11215, United States

  • Local Institution - 0106

    Rehovot, 76100, Israel

  • Local Institution - 0108

    Haifa, 3109601, Israel

  • Local Institution - 0109

    Jerusalem, Jerusalem, 90000, Israel

  • Local Institution - 0110

    Petah Tikva, 49100, Israel

  • Local Institution - 0111

    Beersheba, 84101, Israel

  • Local Institution - 0112

    Be’er Ya‘aqov, 7033001, Israel

  • Local Institution - 0113

    Jerusalem, 9103102, Israel

  • Local Institution - 0114

    Seoul, Seoul Teugbyeolsi, 06351, South Korea

  • Local Institution - 0115

    Zárate, Buenos Aires, B2800DGH, Argentina

  • Local Institution - 0116

    Safed, 1311001, Israel

  • Local Institution - 0117

    Hackensack, New Jersey, 07601-1915, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.